Company / Free Cash Flow
MADRIGAL PHARMACEUTICALS, INC. Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$190.0M
FY2025
5-year range
-$457.0M / -$184.1M
FY2021-FY2025
Trend
+58.4%
vs FY2024
Sector context
#147 of 194
Health Care
What the data says
MADRIGAL PHARMACEUTICALS, INC.'s free cash flow of -$190M is lower than 76% of companies in the Health Care sector (FY2025). Free Cash Flow returned to growth in FY2025 after 8 years of decline, reaching -$190M.
Based on SEC 10-K filings.
-$190M in FY2025.
Improved from -$326M to -$190M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 24% in Health CareTop 76% of 194This company -$190.0M Sector average $470.6M
▼
-140.4% below sector average
Key checks
Key Insights
- In FY2025, free cash flow increased 58.4% year-over-year.
- Ranks #147 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2016.
- Lowest free cash flow in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -0.47 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$190.0M | +58.4% |
| FY2024 | -$457.0M | -40.3% |
| FY2023 | -$325.7M | -44.7% |
| FY2022 | -$225.1M | -22.2% |
| FY2021 | -$184.1M | -16.6% |
| FY2020 | -$157.9M | -277.8% |
| FY2019 | -$41.8M | -63.7% |
| FY2018 | -$25.5M | -13.8% |
| FY2017 | -$22.4M | -27.4% |
| FY2016 | -$17.6M | +77.7% |
As of FY2025 · SEC 10-K · Updated Mar 29, 2026